THE DUBERSTEIN GROUP INC. for PFIZER INC.
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Opiod and prescription drug abuse.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Pharmacy PHA
Pharmaceutical issues, including track and trace legislation - HR 1919, Safeguarding America's Pharmaceuticals Act of 2013; S 957, Drug Supply Chain Security Act; HR 3204, Drug Quality and Security Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
Trade (domestic/foreign) TRD
India treatment of intellectual property. Trans Pacific Partnership negotiation. IP protection standards in GSP - HR 3167, Play Fair on Trade. Miscellaneous tariff bill.Trade Promotion Authority, fast track. Korea treatment of intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Taxation/Internal Revenue Code TAX
Comprehensive tax reform, including international taxes issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Copyright/Patent/Trademark CPT
Patent reform - HR 3309, Innovation Act; S 1720, Patent Transparency and Improvements Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Health Issues HCR
Implementation of the Affordable Care Act. Homeland Security and Agriculture appropriations regarding Certified Importer Program. Vaccines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Medicare/Medicaid MMM
Impact of fiscal deficit issues, including Continuing Resolution extension of Medicare Part D and Medicare rebates - HJ Res 59, Continuing Appropriations Resolution, 2014. Sustainable growth rate - HR 2810, Medicare Patient Access and Quality Improvement Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Impact of budget talks on healthcare issues - HJRes 59, Continuing Appropriations Resolution, 2014
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN GRIFFIN | — |
| DANIEL P MEYER | — |
Consumer Issues/Safety/Products CSP
FDA fees - HR 2725, Food and Drug Administration Safety Over Sequestration Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN CHAMPLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.